News

Home>News>

Cartherics to present at the 2025 BIO International Convention

  • Cartherics’ Chief Operating Officer, Dr. Ian Nisbet, will be presenting at BIO on Monday 16th June, 2025 at 1.30pm (US EDT).

Melbourne, Australia, 28 May 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, […]

2025-05-28T12:11:40+10:00May 28th, 2025|

Bridging Borders: The Strategic Value of U.S.-Based Directors for Australian Biotech Companies

Cartherics’ appointment of Laurence Nore underscores a growing trend with global implications. 

As global demand for biotechnology products and services continues to grow, innovation in the industry is becoming increasingly globalised. Cartherics Pty Ltd, a Melbourne-based biotech company pioneering cell-based immunotherapies, recently announced the appointment of U.S. life sciences executive Laurence Nore to […]

2025-05-19T18:37:06+10:00May 19th, 2025|

The Silent Crisis: The Overlooked Battle for Funding and Treatment in Ovarian Cancer and Endometriosis

Prof. Alan Trounson, AO

Women’s health has suffered long-term disappointments in targeted research and the key funding that needs to be committed to making progress at the level we should expect. Ovarian cancer and endometriosis are two critical women’s health issues with devastating effects and neither has attracted the attention of significant resources to make acceptable […]

2025-05-12T13:39:40+10:00May 12th, 2025|

World Ovarian Cancer Day – Insights from Board Advisor, Heather Hawkins

Today on World Ovarian Cancer Day, we are proud to share the powerful story of Heather Hawkins – ovarian cancer survivor, global marathon runner, patient advocate, and a valued Board Advisor at Cartherics.

After being diagnosed with ovarian cancer in 2007, Heather transformed her experience into a mission of awareness, action, and hope. Her survivorship, combined […]

2025-05-08T10:42:54+10:00May 8th, 2025|

Cartherics appoints new Board Chair and Non-Executive Director

  • Cartherics appoints Prof. Bryan Williams as new Board Chair and Ms. Laurence Nore as Non-Executive Director

Melbourne, Australia, 16 April 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, is pleased to announce the appointment of Prof. Bryan R.G. Williams […]

2025-05-08T09:47:26+10:00April 16th, 2025|

Cartherics strengthens scientific and manufacturing team

Cartherics is pleased to announce that it has made several strategic new appointments to enhance its scientific and manufacturing teams, aligning with the company’s commitment to advancing its growing pipeline of innovative therapies. These new additions are expected to bring in diverse expertise, reinforcing the company’s capabilities in both research and development as well […]

2025-03-20T14:23:43+11:00March 20th, 2025|

Cartherics CEO discusses the future of cancer treatment in The Australian

Cartherics’ CEO, Prof. Alan Trounson, recently contributed to an insightful article in The Weekend Australian, exploring the latest advancements in cell therapy treatments for cancer. We would like to extend our thanks to Natasha Robinson for her thorough and thought-provoking piece that highlights how cell therapy breakthroughs are offering new hope to cancer […]

2025-03-17T11:13:34+11:00March 17th, 2025|

Cartherics comes together to raise awareness and shine a spotlight on ovarian cancer

As Ovarian Cancer Awareness Month draws to a close, the Cartherics team gathered for an afternoon dedicated to raising awareness and funds for ovarian cancer research.

Each year, around 1,800 new ovarian cancer cases are diagnosed in Australia, with over 70% of these being at advanced stages and offering limited treatment options. Cartherics is developing innovative […]

2025-02-27T19:16:15+11:00February 27th, 2025|

iPSC-Derived NK Cells and the Future of Immunotherapy

Induced pluripotent stem cell (iPSC)-derived NK cells are revolutionising cancer immunotherapy by offering a scalable and reliable source of immune cells for therapeutic use. These NK cells are engineered to target and eliminate a wider range of tumours, providing new opportunities for treatment.

Unlike traditional donor-derived NK cells, iPSC-derived NK cells offer a limitless and consistent […]

2025-02-14T09:56:42+11:00February 14th, 2025|

Cartherics presents at Australia and New Zealand’s Biologics Festival

Cartherics’ Chief Operating Officer, Dr. Ian Nisbet recently presented at the 3rd ANZ Biologics Festival at Crown Promenade in Melbourne. His presentation titled, ‘Building a Discovery-to-Clinic Company to Exploit the Full Power of Cell Therapies’ provided insights into Cartherics’ innovative approach to clinical manufacturing and cell therapy development.

The 3rd ANZ Biologics Festival brought together biopharma […]

2025-02-07T12:42:21+11:00February 7th, 2025|
Go to Top